Alternative Solid Forms: Co-crystals

Johan Wouters, Dario Braga, Fabrizia Grepioni, Luc Aerts, Luc Quéré

Résultats de recherche: Contribution dans un livre/un catalogue/un rapport/dans les actes d'une conférenceChapitre


The relevance of co‐crystals for pharmaceutical development is demonstrated by the constant growth of the number of papers and patents published in the two last decades. Co‐crystallization appears to be an efficient means to modulate the solid state properties of a pharmaceutical active ingredient (API) within the crystalline state. It is also a crystal engineering approach enabling to prepare original materials, including co‐drugs. Co‐crystallization is therefore a route to innovation and opens perspectives to patent protection. Alternatively, co‐crystal formation may represent an undesired or unexpected outcome of molecular complexation, for example in the drug product. This observation underlines the importance of a detailed study on the solid state chemistry not only of the pure API, but also of its combinations with the individual components in the formulation.
langue originaleAnglais
titrePolymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development
rédacteurs en chefRolf Hilfiker, Markus von Raumer
Nombre de pages32
Les DOIs
Etat de la publicationPublié - 21 déc. 2018

Empreinte digitale

Examiner les sujets de recherche de « Alternative Solid Forms: Co-crystals ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation